Clinical features of XXXX : a prospective birth cohort.

@entity1 @entity1593 @entity4106 @entity8265 @entity3137 @entity4107
OBJECTIVES: To investigate clinical features of @entity1593 ( @entity1593 ) and their association with risk factors for @entity1593 in a genetic risk birth cohort. METHODS: @entity1 from 6 clinical centers in 4 countries positive for HLA- @entity4106 -DQ2 or @entity4107 -DQ8 were annually screened for @entity8265 antibodies (tTGA) and assessed for symptoms by questionnaires. Associations of symptoms with anthropometrics, known risk factors for @entity1593 , tTGA levels, and @entity3137 in those biopsied were examined. RESULTS: Of 6706 screened @entity1 , 914 developed persistent positive tTGA, 406 underwent biopsies, and 340 had @entity1593 . Compared with age-matched tTGA-negative @entity1 , those with persistent tTGA were more likely to have symptoms at 2 (34% vs 19%, P < .001) and 3 years of age (28% vs 19%, P = .009) but not at 4 years (27% vs 21%, NS). Z-scores for height, weight, and BMI did not differ between groups. In @entity1 with persistent tTGA, having >=  1 symptom was associated with family history of @entity1593 (odds ratio = 2.59, 95% confidence interval, 1.21-5.57) but not with age, gender, or HLA- @entity4106 -DQ2 homozygosity. At seroconversion, tTGA levels were higher in symptomatic than asymptomatic @entity1 (P < .001), in those from @entity1593 families (P < .001), and in US @entity1 (P < .001) but not associated with age, gender, or HLA genotype. tTGA levels correlated with severity of @entity3137 both in symptomatic (r = 0.53, P < .001) and asymptomatic @entity1 (r = 0.22, P = .01). CONCLUSIONS: A majority of @entity1 detected with persistent tTGA in screenings are asymptomatic and have normal growth by age 4 years. tTGA levels correlate more strongly with severity of @entity3137 in symptomatic as compared with asymptomatic @entity1 .
